Pharma Companies

USFDA issues warning letter to Aurobindo Pharma's Telangana facility

Aurobindo Pharma on Friday said the US health regulator has issued a warning letter to a formulation manufacturing facility of its arm, Eugia Pharma Specialities Ltd, in Telangana. In May this year the company had stated that the US Food and Drug Administration (USFDA) inspected Unit-I, a formulation manufacturing facility of Eugia Pharma Specialities Ltd located at Telangana from February 16 to February 27, 2026. The inspection had concluded with four observations and the USFDA had determined the facility as 'official action indicated' (OAI). "Subsequent to OAI, the unit has received a warning letter," Aurobindo Pharma said in a regulatory filing. There is no impact on the existing supplies to the US markets, it added. The company further said the Unit I of Eugia Pharma Specialities Ltd, is contributing to about 2 per cent to company's overall group revenue. Aurobindo Pharma said it remains committed to working closely with the US FDA and continues to enhance its compliance on a

Indegene eyes clinical research acquisition to widen pharma services play

The company is evaluating specialised CROs, data-management and patient-recruitment businesses as it looks to expand across the pharmaceutical value chain

Piramal Pharma eyes mid-teens growth in FY27, prioritises organic expansion

Higher capacity utilisation, operating leverage and broad-based demand across CDMO, hospital generics and consumer healthcare are expected to support margins in FY27

Sun Pharma to launch semaglutide in Brazil with Hypera Pharma soon

Sun Pharma will launch the once-weekly diabetes treatment through Hypera Pharma as generic competition intensifies in Brazil's $413 million semaglutide market

​AstraZeneca beats second-quarter profit expectations, holds outlook

The drugmaker reported better-than-expected second-quarter earnings, driven by strong demand for cancer and rare disease therapies

Pentagon names WuXi AppTec on Chinese military firms list, raising concerns

Any restriction that stems from the designation could have broader implications because WuXi AppTec helps conduct research and development efforts on behalf of many US drugmakers

'Uzbekistan can offer incentives for Indian pharmas to boost investments'

Uzbekistan could offer enhanced subsidies and technology transfer incentives to encourage greater investment from Indian pharmaceutical companies, strengthening its position as a regional hub for pharmaceutical manufacturing and supply, Deputy Minister of Investment, Industry and Trade Shokhrukh Gulamov has said. "To expand local pharmaceutical manufacturing, Uzbekistan could adopt policies that simplify regulatory approvals and strengthen investment incentives. Streamlined licensing procedures, reduced bureaucratic barriers, and predictable regulatory timelines would make local production more attractive," he told PTI. Tax incentives and subsidies for technology transfer, industrial cluster participation, and export-oriented production could further encourage investment, he said. "Access to well-equipped industrial zones and joint ventures with local partners can accelerate production capacity while ensuring compliance with quality standards. Protection of intellectual property and

Venus Remedies gets Saudi FDA nod for speciality oncology therapy

Pharma major Venus Remedies Limited on Saturday said it has received marketing authorisation from the Saudi Food and Drug Authority (SFDA) for speciality oncology therapy -- Plerixafor. Plerixafor is a hematopoietic stem cell mobiliser used in combination with granulocyte-colony stimulating factor (G-CSF) to mobilise stem cells into peripheral blood for collection and autologous transplantation. It is standard-of-care in haemato-oncology, particularly for patients with multiple myeloma and non-Hodgkin lymphoma undergoing transplant, the company said in a statement. This is the first marketing authorisation the company secured for Plerixafor anywhere in the world, it added. Saransh Chaudhary, President, Global Critical Care, Venus Remedies Limited, and Venus Medicine Research Centre CEO, said, "This is our first Plerixafor approval anywhere in the world, and Saudi Arabia is the right market to launch it in". "Plerixafor sits squarely in the kind of therapy class we are building our

Alembic Pharma shares plunge 9% on soft Q4 results, weak margins drag

Alembic Pharmaceuticals reported a 29 per cent year-on-year (Y-o-Y) rise in consolidated net profit to ₹202 crore as compared to ₹157 crore in the year-ago period

Cipla Q4 results: Net profit falls 54.6% to ₹555 crore, revenue drops 2.8%

Total revenue from operations fell 2.8 per cent to ₹6,541 crore, below the average expectations of ₹6,749 crore, hurt by a sales decline in its key North America market

Cipla Q4 preview: Profit may plunge on weak US sales; check estimates here

Cipla's March 2026 quarter revenue is expected to decline marginally to ₹6,665 crore as compared to ₹6,730 crore in the year-ago period

Dr Reddy's Q4 preview: Lower US sales to drag earnings; profit may dip 34%

Dr Reddy's net profit is expected to come at ₹1,035 crore, marking a moderate 34 per cent Y-o-Y decrease, on average, as against ₹1,587 crore in the Q4FY25

Sun Pharma weighs multiple funding options for $12 billion Organon deal

The Indian drugmaker is considering seeking consent from Organon bondholders to swap their holdings into Sun Pharma debt

Sun Pharma's $11.75 bn Organon bet: Global pharma leap or balance risk?

Sun Pharma's $11.75 billion Organon deal could boost its global scale and biosimilars reach, but investors are closely watching debt levels, execution risks and long-term returns

Sun Pharmaceutical acquires US-based Organon in $11.75 billion deal

Combined entity to have revenue of $12.4 billion; enters biosimilars big league

Sun Pharma to acquire US drugmaker Organon in $11.75 billion all-cash deal

April 26 (Reuters) - India's Sun Pharmaceutical Industries ​will uy Organon & ​Co in an all-cash ‌deal, valuing the U.S. drugmaker at about $11.75 billion including ebt, the companies said on Sunday.

Govt plans to bar cough syrups for kids under 2 amid safety concerns

Draft NFI 2026 bars use for children under two, discourages it below five, and mandates stricter testing of ingredients after contamination-linked deaths raised global alarm

IPM growth at 10.5% marks 5-qtr high on steady pricing, volume recovery

Indian pharma market's growth was led more by price increases that an uptick in consumption

Centre increases monitoring of weight-loss drugs, flags safety concerns

Regulators have been asked to track adverse events as India tightens oversight on popular obesity drugs amid rising demand and concerns over misuse and misleading promotions

Sai Parenteral's to launch IPO on March 24; eyes ₹285 crore via fresh issue

Sai Parenteral's IPO comprises a fresh issue of ₹285 crore and an offer for sale (OFS) of 3.2 million equity shares